The cases presented are in line with a growing body of clinical and preclinical evidence that indicating that NSCLC with various uncommon <i>EGFR</i> mutations, with or without co-mutations, may be sensitive to afatinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.